3LKJ | C:138-261; C:138-261; C:138-261 | SMALL MOLECULE INHIBITION OF THE TNF FAMILY CYOKINE CD40 LIGAND THROUGH A SUBUNIT FRACTURE MECHANISM |
3QD6 | F:138-261; F:138-261; F:138-261; F:138-261; F:138-261; F:138-261 | CRYSTAL STRUCTURE OF THE CD40 AND CD154 (CD40L) COMPLEX |
1RJ7 | M:272-385; M:272-385; M:272-385; M:272-385; M:272-385; M:272-385; M:272-385; M:272-385; M:272-385; M:272-385; M:272-385; M:272-385 | CRYSTAL STRUCTURE OF EDA-A1 |
1JH5 | J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143 | CRYSTAL STRUCTURE OF STALL-1 OF TNF FAMILY LIGAND |
1KD7 | M:168-284; M:168-284; M:168-284; M:168-284; M:168-284; M:168-284 | CRYSTAL STRUCTURE OF AN EXTRACELLULAR DOMAIN FRAGMENT OF HUMAN BAFF |
1KXG | F:168-284; F:168-284; F:168-284; F:168-284; F:168-284; F:168-284 | THE 2.0 ANG RESOLUTION STRUCTURE OF BLYS, B LYMPHOCYTE STIMULATOR. |
1OQD | J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143 | CRYSTAL STRUCTURE OF STALL-1 AND BCMA |
1OQE | J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143; J:27-143 | CRYSTAL STRUCTURE OF STALL-1 WITH BAFF-R |
1OSG | F:168-284; F:168-284; F:168-284; F:168-284; F:168-284; F:168-284 | COMPLEX BETWEEN BAFF AND A BR3 DERIVED PEPTIDE PRESENTED IN A BETA-HAIRPIN SCAFFOLD |
2O0O | C:117-251; C:117-251; C:117-251 | CRYSTAL STRUCTURE OF TL1A |
2QE3 | A:50-184 | CRYSTAL STRUCTURE OF HUMAN TL1A EXTRACELLULAR DOMAIN |
2RE9 | C:46-180; C:46-180; C:46-180 | CRYSTAL STRUCTURE OF TL1A AT 2.1 A |
2RJK | A:50-184 | CRYSTAL STRUCTURE OF HUMAN TL1A EXTRACELLULAR DOMAIN C95S MUTANT |
2RJL | A:50-184 | CRYSTAL STRUCTURE OF HUMAN TL1A EXTRACELLULAR DOMAIN C95S/C135S MUTANT |
3K51 | A:50-184 | CRYSTAL STRUCTURE OF DCR3-TL1A COMPLEX |
3MI8 | A:50-184 | THE STRUCTURE OF TL1A-DCR3 COMPLEX |
2Q1M | A:67-155 | CRYSTAL STRUCTURE OF HUMAN GITRL |
2R30 | A:67-155 | CRYSTAL STRUCTURE OF HUMAN GITRL MUTANT |
2R32 | A:67-155 | CRYSTAL STRUCTURE OF HUMAN GITRL VARIANT |
1TNF | C:26-157; C:26-157; C:26-157 | THE STRUCTURE OF TUMOR NECROSIS FACTOR-ALPHA AT 2.6 ANGSTROMS RESOLUTION. IMPLICATIONS FOR RECEPTOR BINDING |
2TUN | F:26-157; F:26-157; F:26-157; F:26-157; F:26-157; F:26-157 | CONFORMATIONAL CHANGES IN THE (ALA-84-VAL) MUTANT OF TUMOR NECROSIS FACTOR |
2ZJC | C:26-157; C:26-157; C:26-157 | TNFR1 SELECTVE TNF MUTANT; R1-6 |
2ZPX | C:26-157; C:26-157; C:26-157 | TNF RECEPTOR SUBTYPE ONE-SELECTIVE TNF MUTANT WITH ANTAGONISTIC ACTIVITY; R1ANTTNF-T8 |
3L9J | T:26-157 | SELECTION OF A NOVEL HIGHLY SPECIFIC TNFALPHA ANTAGONIST: INSIGHT FROM THE CRYSTAL STRUCTURE OF THE ANTAGONIST-TNFALPHA COMPLEX |
1TNR | A:43-171 | CRYSTAL STRUCTURE OF THE SOLUBLE HUMAN 55 KD TNF RECEPTOR-HUMAN TNF-BETA COMPLEX: IMPLICATIONS FOR TNF RECEPTOR ACTIVATION |
2X29 | A:107-240 | CRYSTAL STRUCTURE OF HUMAN4-1BB LIGAND ECTODOMAIN |